These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20616953)

  • 21. Novel agents for myelodysplastic syndromes.
    Xu K; Hansen E
    J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
    Lee BH; Kang KW; Jeon MJ; Yu ES; Kim DS; Choi H; Lee SR; Sung HJ; Kim BS; Choi CW; Park Y
    Sci Rep; 2020 Jan; 10(1):39. PubMed ID: 31913293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
    Garcia-Manero G; Fenaux P
    J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decitabine.
    Hackanson B; Daskalakis M
    Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
    Hu N; Qin T; Du X; Wang B; Wang X; Xu Z; Pan L; Qu S; Xiao Z
    Med Sci Monit; 2021 Jan; 27():e928454. PubMed ID: 33514682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.
    Ding K; Fu R; Liu H; Nachnani DA; Shao ZH
    Oncol Lett; 2016 Apr; 11(4):2347-2352. PubMed ID: 27073478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
    Almasri J; Alkhateeb HB; Firwana B; Sonbol MB; Damlaj M; Wang Z; Murad MH; Al-Kali A
    Syst Rev; 2018 Sep; 7(1):144. PubMed ID: 30227896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy with azanucleosides for myelodysplastic syndromes.
    Quintás-Cardama A; Santos FP; Garcia-Manero G
    Nat Rev Clin Oncol; 2010 Aug; 7(8):433-44. PubMed ID: 20551943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of hypomethylating agents in the treatment of hematologic malignancies.
    Kihslinger JE; Godley LA
    Leuk Lymphoma; 2007 Sep; 48(9):1676-95. PubMed ID: 17786703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update on the treatment of myelodysplastic syndromes.
    Kurtin SE; Demakos EP
    Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
    Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The revolution of myelodysplastic syndromes.
    Sekeres MA; Bejanyan N
    Ther Adv Hematol; 2011 Feb; 2(1):33-43. PubMed ID: 23556074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
    Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
    Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.